ACRP CP CERTIFICATION EXAM – QUESTIONS AND ANSWERS | VERIFIED AND WELL DETAILED ANSWERS | PLUS
RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains
1. Clinical Trial Design and Methodology
2. Regulatory and Legal Compliance (ICH GCP, FDA, EMA)
3. Ethical Principles and Patient Safety (HIPAA, Informed Consent)
4. Study Site Management and Monitoring
5. Data Management and Biostatistics Fundamentals
6. Pharmacovigilance and Adverse Event Reporting
7. Leadership, Communication, and Professional Standards
Introduction
This comprehensive assessment is designed to rigorously prepare candidates for the ACRP CP certification examination.
It evaluates a broad spectrum of knowledge essential for the clinical research professional, from foundational ethical
principles and regulatory frameworks to complex, real-world decision-making in study management. The following 200
multiple-choice questions, structured in a scenario-based format, are crafted to test not only recall but also the critical
thinking and application skills required to excel in the field. This practice exam emphasizes the practical application of
ICH GCP guidelines, patient safety protocols, and effective site management, ensuring candidates are well-prepared for
the challenges of modern clinical research.
SECTION ONE: QUESTIONS 1 – 100
1. A principal investigator (PI) decides to modify the inclusion criteria for a study without prior IRB approval to
enroll a patient who would otherwise be excluded. Which regulation has the PI violated?
,A. 21 CFR Part 11
B. ICH GCP E6(R2)
C. The Declaration of Helsinki
D. HIPAA Privacy Rule
🟢 B. ICH GCP E6(R2)
🔴 Explanation: ICH GCP E6(R2) mandates that any deviation from the approved protocol must be reviewed and
approved by the IRB/IEC prior to implementation, except when necessary to eliminate an immediate hazard to
subjects. This action represents a significant protocol violation.
2. When conducting a clinical trial, which document provides the most detailed description of a study's design,
methodology, and statistical analysis plan?
A. Investigator’s Brochure (IB)
B. Clinical Study Report (CSR)
C. Protocol
D. Informed Consent Form (ICF)
🟢 C. Protocol
🔴 Explanation: The protocol is the central document that outlines the objectives, design, methodology, statistical
considerations, and organization of a clinical trial. It is the master plan for the study.
3. A study coordinator discovers that a subject's scheduled 12-week visit was conducted on day 85 instead of day
84. The protocol specifies a visit window of ± 3 days. What is the most appropriate action?
A. Ignore the deviation as it is within a week.
B. Report the deviation to the IRB immediately.
,C. Document the deviation as a protocol violation.
D. Do nothing, as it falls within the acceptable visit window.
🟢 D. Do nothing, as it falls within the acceptable visit window.
🔴 Explanation: Since the visit occurred on day 85, which is within the protocol-specified window of 84 days ± 3
days (days 81-87), it is not a deviation. The visit is considered compliant with the protocol.
4. What is the primary purpose of the Investigator’s Brochure (IB)?
A. To advertise the study to potential subjects.
B. To provide financial disclosure information to the sponsor.
C. To compile the clinical and non-clinical data on the investigational product.
D. To serve as the contract between the sponsor and the investigative site.
🟢 C. To compile the clinical and non-clinical data on the investigational product.
🔴 Explanation: The Investigator's Brochure is a comprehensive document summarizing the investigational
product's pharmacology, toxicology, pharmacokinetics, and clinical data from previous studies. It is intended to
inform investigators about the product's safety and efficacy profile.
5. According to HIPAA, which of the following is considered Protected Health Information (PHI)?
A. A subject's initials
B. A subject's zip code
C. A subject's medical record number
D. All of the above
🟢 D. All of the above
, 🔴 Explanation: Under the HIPAA Privacy Rule, PHI includes any information that can be used to identify an
individual, including initials, geographic data (like zip code), and medical record numbers. These are all considered
identifiers.
6. An auditor identifies that an investigator signed the study protocol three weeks after the first subject was
enrolled. This is a major finding because it constitutes:
A. A violation of FDA regulations on financial disclosure.
B. A breach of the IRB's continuing review requirements.
C. A lack of investigator commitment to the protocol.
D. A significant protocol violation, as the PI must sign the protocol before enrolling subjects.
🟢 D. A significant protocol violation, as the PI must sign the protocol before enrolling subjects.
🔴 Explanation: The PI's signature on the protocol signifies their agreement to conduct the study according to its
terms. This signature must be obtained prior to the enrollment of the first subject to ensure the PI has reviewed and
accepted the protocol's conditions.
7. The principle of 'Equipoise' in clinical research is best described as:
A. A state of genuine uncertainty within the expert medical community about the comparative therapeutic merits of
each arm in a trial.
B. An equal distribution of male and female subjects in a study.
C. A balance between the risks and benefits of a study.
D. A legal requirement for informed consent.
🟢 A. A state of genuine uncertainty within the expert medical community about the comparative therapeutic merits
of each arm in a trial.
RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains
1. Clinical Trial Design and Methodology
2. Regulatory and Legal Compliance (ICH GCP, FDA, EMA)
3. Ethical Principles and Patient Safety (HIPAA, Informed Consent)
4. Study Site Management and Monitoring
5. Data Management and Biostatistics Fundamentals
6. Pharmacovigilance and Adverse Event Reporting
7. Leadership, Communication, and Professional Standards
Introduction
This comprehensive assessment is designed to rigorously prepare candidates for the ACRP CP certification examination.
It evaluates a broad spectrum of knowledge essential for the clinical research professional, from foundational ethical
principles and regulatory frameworks to complex, real-world decision-making in study management. The following 200
multiple-choice questions, structured in a scenario-based format, are crafted to test not only recall but also the critical
thinking and application skills required to excel in the field. This practice exam emphasizes the practical application of
ICH GCP guidelines, patient safety protocols, and effective site management, ensuring candidates are well-prepared for
the challenges of modern clinical research.
SECTION ONE: QUESTIONS 1 – 100
1. A principal investigator (PI) decides to modify the inclusion criteria for a study without prior IRB approval to
enroll a patient who would otherwise be excluded. Which regulation has the PI violated?
,A. 21 CFR Part 11
B. ICH GCP E6(R2)
C. The Declaration of Helsinki
D. HIPAA Privacy Rule
🟢 B. ICH GCP E6(R2)
🔴 Explanation: ICH GCP E6(R2) mandates that any deviation from the approved protocol must be reviewed and
approved by the IRB/IEC prior to implementation, except when necessary to eliminate an immediate hazard to
subjects. This action represents a significant protocol violation.
2. When conducting a clinical trial, which document provides the most detailed description of a study's design,
methodology, and statistical analysis plan?
A. Investigator’s Brochure (IB)
B. Clinical Study Report (CSR)
C. Protocol
D. Informed Consent Form (ICF)
🟢 C. Protocol
🔴 Explanation: The protocol is the central document that outlines the objectives, design, methodology, statistical
considerations, and organization of a clinical trial. It is the master plan for the study.
3. A study coordinator discovers that a subject's scheduled 12-week visit was conducted on day 85 instead of day
84. The protocol specifies a visit window of ± 3 days. What is the most appropriate action?
A. Ignore the deviation as it is within a week.
B. Report the deviation to the IRB immediately.
,C. Document the deviation as a protocol violation.
D. Do nothing, as it falls within the acceptable visit window.
🟢 D. Do nothing, as it falls within the acceptable visit window.
🔴 Explanation: Since the visit occurred on day 85, which is within the protocol-specified window of 84 days ± 3
days (days 81-87), it is not a deviation. The visit is considered compliant with the protocol.
4. What is the primary purpose of the Investigator’s Brochure (IB)?
A. To advertise the study to potential subjects.
B. To provide financial disclosure information to the sponsor.
C. To compile the clinical and non-clinical data on the investigational product.
D. To serve as the contract between the sponsor and the investigative site.
🟢 C. To compile the clinical and non-clinical data on the investigational product.
🔴 Explanation: The Investigator's Brochure is a comprehensive document summarizing the investigational
product's pharmacology, toxicology, pharmacokinetics, and clinical data from previous studies. It is intended to
inform investigators about the product's safety and efficacy profile.
5. According to HIPAA, which of the following is considered Protected Health Information (PHI)?
A. A subject's initials
B. A subject's zip code
C. A subject's medical record number
D. All of the above
🟢 D. All of the above
, 🔴 Explanation: Under the HIPAA Privacy Rule, PHI includes any information that can be used to identify an
individual, including initials, geographic data (like zip code), and medical record numbers. These are all considered
identifiers.
6. An auditor identifies that an investigator signed the study protocol three weeks after the first subject was
enrolled. This is a major finding because it constitutes:
A. A violation of FDA regulations on financial disclosure.
B. A breach of the IRB's continuing review requirements.
C. A lack of investigator commitment to the protocol.
D. A significant protocol violation, as the PI must sign the protocol before enrolling subjects.
🟢 D. A significant protocol violation, as the PI must sign the protocol before enrolling subjects.
🔴 Explanation: The PI's signature on the protocol signifies their agreement to conduct the study according to its
terms. This signature must be obtained prior to the enrollment of the first subject to ensure the PI has reviewed and
accepted the protocol's conditions.
7. The principle of 'Equipoise' in clinical research is best described as:
A. A state of genuine uncertainty within the expert medical community about the comparative therapeutic merits of
each arm in a trial.
B. An equal distribution of male and female subjects in a study.
C. A balance between the risks and benefits of a study.
D. A legal requirement for informed consent.
🟢 A. A state of genuine uncertainty within the expert medical community about the comparative therapeutic merits
of each arm in a trial.
